Relationships with debuts
New listing of the company GENXONE S.A. on NewConnect
GENXONE S.A. was newly listed on NewConnect on 25 August 2020.
GENXONE S.A is the 374th company listed on NewConnect and the 8th new listing on NewConnect in 2020.
Key information
|
company name |
GENXONE S.A. |
|
seat |
Złotniki |
|
companies listed on NC |
374 |
|
new listings on NC in 2020 r. |
8 |
|
business sector |
Biotechnology |
|
companies in the sector |
11 |
|
core business |
The Issuer operates in the biotechnology industry and offers nucleic acid nanopore sequencing technology. |
|
subscription/sale |
- offering of 350,000 series B shares at an issue price of PLN 4.90, total offering value PLN 1,715,000; - offering of 306,000 series C shares at an issue price of PLN 4.90, total offering value PLN 1,499,400; - offering of 600,000 series D shares at an issue price of PLN 6.90, total offering value PLN 4,140,000; - sale of the Issuer’s shares at prices from PLN 1 to PLN 9, total sale value PLN 2,812,729.76; |
|
reference price* |
PLN 6.9 |
|
company valuation* |
PLN 22,735,500 |
|
valuation of introduced instruments* |
PLN 22,735,500 |
|
%free float (under 5% in shares subject to the application) |
33.85 |
|
free float value* (shares subject to the application) |
PLN 7,696.287.6 |
|
%free float (under 5% in all shares) |
33.85 |
|
free float value* (all shares) |
PLN 7,696.287.6 |
|
Number of shareholders |
82 |
|
Authorised Advisor |
INC S.A. |
|
Market Maker |
Dom Maklerski BDM S.A. |
*reference price at the issue price of series D shares
Historia/Core business
The operating activities of genXone Sp. z o.o., including investments in its first lab (R&D Lab), started in Q4 2016. The transformation of the Issuer into a joint-stock company was registered in the National Court Register in Q3 2018.
The Issuer operates in the biotechnology industry and offers nucleic acid nanopore sequencing technology based on Next-Generation Sequencing (NGS).
On 28 June 2018, the Wielkopolska Voivode issued a certificate of the Issuer’s entry into the registry of medical operators.
On 20 August 2019, the Issuer received a resolution of the Board of the National Chamber of Laboratory Diagnosticians concerning the entry of the Issuer’s medical diagnostic laboratory into the national laboratory register.
On 30 March 2020, the Issuer was entered into the list of regional laboratories testing for SARS-CoV-2.
The Company’s share capital according to the entry in the Companies Register is PLN 3,295,000 divided into 3,295,000 series A, B, C and D ordinary bearer shares with a nominal value of PLN 1 per share.
Offering of 350,000 series B shares
The subscription opened on 21 November 2018 and closed on 30 April 2019. Series B shares were taken up at an issue price of PLN 4.90.
Offering of 306,000 series C shares
The subscription opened on 27 May 2019 and closed on 27 June 2019. Series C shares were taken up at an issue price of PLN 4.90.
Offering of 600,000 series D shares
The subscription opened on 3 March 2020 and closed on 8 April 2020. Series D shares were taken up at an issue price of PLN 6.90.
Sale of shares by shareholders
According to the information document, from 21 January 2019 to 27 July 2020, there were 23 sale transactions in 638,437 of the Issuer’s shares at prices ranging from PLN 1 to PLN 9. The total value of the sale was PLN 2,812,729.76.
Shareholders
|
Shareholder |
Number of shares (#) |
Stake in the share capital (%) |
Stake in votes (%) |
|
||
|
TOROX EKO Fizan |
656,768 |
19.93 |
19.93 |
|
||
|
Michał Kaszuba* |
471,500 |
14.31 |
14.31 |
|
||
|
MEDCAMP S.A.** Diagnostyka Sp. z o.o. Carpathia Capital S.A. Seppi Investment LTD*** Moonrock Enterprise S.A. Other |
436,852 361,407 253,069 11,415 21,155 1,082,834 |
13.26 10.97 7.68 0.35 0.64 32.86 |
13.26 10.97 7.68 0.35 0.64 32.86 |
|
||
|
Total 3,295,000
|
100 |
100
|
||||
|
|
|
|
|
|
|
|
*including persons in an implicit agreement
**Moonrock Enterprise S.A. holds 14.74% of shares equal to 14.74% of votes in Medcamp SA
***Moonrock Enterprise S.A. holds 100% of shares of Seppi Investment LTD
The Issuer’s selected financials (PLN):
|
|
Q1 2020 |
2019 |
2018 |
|
Equity |
3,417,196.99 |
3,769,124.36 |
1,632,099.01 |
|
Liabilities and provisions |
4,566,997.19 |
3,260,816.96 |
2,861,608.79 |
|
Total assets |
7,984,194.18 |
7,029,941.32 |
4,493,707.80 |
|
Net sales revenue |
132,174.53 |
204,588.71 |
56,726.36 |
|
Net profit |
(351,927.37) |
(1,077,374.65) |
(626,819.76) |
|
Total net cash flows |
566,038.94
|
75,691.19
|
215,745.63
|
|
Cash - closing balance |
886,986.05 |
320,947.11 |
245,255.92 |
3,295,000 series A, B, C and D ordinary bearer shares issued by GENXONE S.A. were introduced to trading on NewConnect.